Clinical Validation of a Blood-Based Predictive Test for Stratification of Response to Tumor Necrosis Factor Inhibitor Therapies in Rheumatoid Arthritis Patients
Open Access
- 1 July 2020
- journal article
- research article
- Published by Mary Ann Liebert Inc in Network and Systems Medicine
- Vol. 3 (1), 91-104
- https://doi.org/10.1089/nsm.2020.0007
Abstract
Objectives: For rheumatoid arthritis (RA) patients failing to achieve treatment targets with conventional synthetic disease-modifying antirheumatic drugs, tumor necrosis factor (TNF)-α inhibitors (anti-TNF therapies) are the primary first-line biologic therapy. In a cross-cohort, cross-platform study, we developed a molecular test that predicts inadequate response to anti-TNF therapies in biologic-naive RA patients. Materials and Methods: To identify predictive biomarkers, we developed a comprehensive human interactome—a map of pairwise protein/protein interactions—and overlaid RA genomic information to generate a model of disease biology. Using this map of RA and machine learning, a predictive classification algorithm was developed that integrates clinical disease measures, whole-blood gene expression data, and disease-associated transcribed single-nucleotide polymorphisms to identify those individuals who will not achieve an ACR50 improvement in disease activity in response to anti-TNF therapy. Results: Data from two patient cohorts (n=58 and n=143) were used to build a drug response biomarker panel that predicts nonresponse to anti-TNF therapies in RA patients, before the start of treatment. In a validation cohort (n=175), the drug response biomarker panel identified nonresponders with a positive predictive value of 89.7 and specificity of 86.8. Conclusions: Across gene expression platforms and patient cohorts, this drug response biomarker panel stratifies biologic-naive RA patients into subgroups based on their probability to respond or not respond to anti-TNF therapies. Clinical implementation of this predictive classification algorithm could direct nonresponder patients to alternative targeted therapies, thus reducing treatment regimens involving multiple trial and error attempts of anti-TNF drugs.Keywords
This publication has 139 references indexed in Scilit:
- RNA-Seq Profiling Reveals Novel Hepatic Gene Expression Pattern in Aflatoxin B1 Treated RatsPLOS ONE, 2013
- Landscape of transcription in human cellsNature, 2012
- Five amino acids in three HLA proteins explain most of the association between MHC and seropositive rheumatoid arthritisNature Genetics, 2012
- Reprogramming transcription by distinct classes of enhancers functionally defined by eRNANature, 2011
- A framework for variation discovery and genotyping using next-generation DNA sequencing dataNature Genetics, 2011
- Network medicine: a network-based approach to human diseaseNature Reviews Genetics, 2010
- Phenopedia and Genopedia: disease-centered and gene-centered views of the evolving knowledge of human genetic associationsBioinformatics, 2009
- Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot projectNature, 2007
- CD4+CD25+ regulatory T cells in rheumatoid arthritis: Differences in the presence, phenotype, and function between peripheral blood and synovial fluidArthritis & Rheumatism, 2004